Astellas Pharma Inc: Macular Degeneration trials

The registry lists 27 Macular Degeneration studies with Astellas Pharma Inc as lead sponsor. 3 are open to participants now and 11 have results posted.

Phase 1 9Phase 2 10Phase 3 6Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye ConditionsRecruitingNCT07734064Phase 1
• A Study to Learn How Stargardt-type Eye Conditions Progress in Children and AdultsRecruitingNCT07425574
• A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationRecruitingNCT03178149Phase 1
• Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMDTerminatedNCT05571267Phase 2Results posted
• Avacincaptad Pegol Open-Label Extension for Patients With Geographic AtrophyCompletedNCT05536297Phase 3Results posted
• A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)CompletedNCT04435366Phase 3Results posted
• ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)CompletedNCT03362190Phase 2Results posted
• Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationCompletedNCT02686658Phase 2/3Results posted
• A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)TerminatedNCT02387957Phase 2Results posted
• Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMDTerminatedNCT02214628Phase 2Results posted
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedNCT01944839Phase 3Results posted
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedNCT01940900Phase 3Results posted
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® MonotherapyTerminatedNCT01940887Phase 3Results posted
• A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular DegenerationCompletedNCT01089517Phase 2Results posted
• A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular DegenerationActive, not recruitingNCT06970665Phase 4
• A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic AtrophyActive, not recruitingNCT06779773
• A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)CompletedNCT02941991
• Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMDWithdrawnNCT02563782Phase 2
• Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMDCompletedNCT02463344
• Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy PatientsCompletedNCT02445612
• Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)CompletedNCT01469832Phase 1/2
• Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular DystrophyCompletedNCT01345006Phase 1/2
• Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular DegenerationCompletedNCT01344993Phase 1/2
• A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular DegenerationCompletedNCT00950638Phase 1
• A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular DegenerationCompletedNCT00782093Phase 1
• ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular DegenerationCompletedNCT00709527Phase 1
• A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular DegenerationCompletedNCT00569140Phase 1